Breaking News

Allergan Files Suit Alleging Pershing, Valeant Violate SEC Rule
Tweet TWEET

MolecularHealth demonstrates Personalized Cancer Therapy Solutions at 2013 CeBIT

  MolecularHealth demonstrates Personalized Cancer Therapy Solutions at 2013
                                    CeBIT

Treatment Decision Support Solutions presented at MolecularHealth Partner, SAP
AG, Booth

PR Newswire

NEW YORK and HEIDELBERG, Germany, March 5, 2013

NEW YORK and HEIDELBERG, Germany, March 5, 2013 /PRNewswire/ --
MolecularHealth, a leader in clinico-molecular informatics™, today announced
that the company will demonstrate their latest capabilities at CeBIT 2013,
taking place in Hannover, Germany March 5-9. The company is advancing
precision medicine by providing decision support solutions that translate
patient-specific molecular and genomic data, treatment-relevant clinical
history, and published scientific evidence in combination with mechanism-based
therapy knowledge into safer, more effective drug choices. MolecularHealth's
Personalized Cancer Therapy Solutions offer health providers and patients an
integrated service that unlocks evidence-based treatment strategies from the
genome, patient clinical history and extensive knowledge about drug therapy
mechanisms of action.

(Logo: http://photos.prnewswire.com/prnh/20130305/DA68911LOGO)

Benefitting from the unprecedented speed and performance of the SAP HANA®
platform, the offering aims to tackle the challenges of immense bodies of
disparate medical, biological and drug data, manual and time consuming
analysis, and the increasingly complex treatment paradigms affecting
pathologists, oncologists and patients and their families. MolecularHealth
will demonstrate its Molecular Analysis of Side Effects™ (MASE) and Oncology
Decision Support capabilities in the SAP booth, Hall 4 Stand C04. These
capabilities reflect SAP's recent entry with the SAP HANA platform and
partners such as MolecularHealth into the increasingly accessible field of
genomics and next generation sequencing-driven clinical decision support.

About MolecularHealth

MolecularHealth, a clinico-molecular informatics company offering
mechanism-based drug safety and Personalized Cancer Therapy Solutions, is
advancing precision medicine by translating patient-specific molecular and
genomic data, clinical history, drug knowledge and published scientific and
medical evidence into safer, more effective drug choices for patients. The
company's solutions range from a next generation drug safety assessment and
prediction tool that analyzes the molecular basis of adverse events to a
treatment decision support offering that informs evidence-based treatment
strategies for cancer patients. MolecularHealth's collaborators include the
University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and
Drug Administration (FDA). Visit www.molecularhealth.com.

© 2013 The MolecularHealth name andlogoare trademarks of Molecular Health
AG.

SAP, SAP HANA, and all SAP logos are trademarks or registered trademarks of
SAP AG in Germany and in several other countries.
All other product and service names mentioned are the trademarks of their
respective companies.

SOURCE MolecularHealth

Website: http://www.molecularhealth.com
Contact: Eric M. Stone, Vice President, Sales and Marketing, MolecularHealth,
+1-646-233-4583, Eric.Stone@molecularhealth.com